A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PEG / pegylated

[Related PubMed/MEDLINE]
Total Number of Papers: 138
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PEG  (>> Co-occurring Abbreviation)
Long Form:   pegylated
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Antiviral treatment withpegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis. CHD, CI, CR, ET, HBsAg, HCC, HDV, NR, OR, PR, qHBsAg
2019 Biotin functionalized PEGylated poly(amidoamine) dendrimer conjugate for active targeting of paclitaxel in cancer. PAMAM, PTX
2019 Pegylated Human Leptin D23L Mutant-Preparation and Biological Activity In Vitro and In Vivo in Male ob/ob Mice. hLEP
2018 Arginase 1 promotes retinal neurovascular protection from ischemia through suppression of macrophage inflammatory responses. IR, KO, NO, NOS, WT
2018 Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. AE, CI, FN, NSCLC
2018 Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naive patients from India. CHC, CI, HCV, OR, RBV, SVR
2018 Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. ALL, ASP
2018 Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis. CHB, IFN, SR
2018 In Vivo Quantitative Understanding of PEGylated Liposome's Influence on Brain Delivery of Diphenhydramine. BBB, DPH
10  2018 Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis. EDSS, GDP, ICER, IRR, MS, QALY, USFDA
11  2018 Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. IFN, PD-1, PFS
12  2018 The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100. ALL, ASS, OTC
13  2017 Biocompatibility assessment of functionalized magnetic mesoporous silica nanoparticles in human HepaRG cells. M-MSNs, TEM
14  2017 Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. IFN, IFNL4, ISGs, LD, SNPs
15  2017 Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. DAAs, HCV, IFN-alpha, ISDR, PKRBD, RBV, SVR
16  2017 Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. CHB, IFNlamda
17  2017 Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. GT2, IFN
18  2017 The impact of liver steatosis on early and sustained treatment response in chronic hepatitis C patients. anti-HCV, AST, AUC, EVR, HCV, IFN-alpha, SVR
19  2017 Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. CHC, DAAs, IFN, RBV
20  2016 Comparison of sleep disorders in chronic hepatitis C patients treated with interferon-based therapy and direct acting antivirals using actigraphy. CHC, DAA, IFN, RBV, SMV
21  2016 Drug Pricing Evolution in Hepatitis C. DAAs, HCV, IFN, RBV, SVR, US
22  2016 Host - hepatitis C viral interactions: The role of genetics. CHC, HCV, IFN
23  2016 PEG-asparaginase induced severe hypertriglyceridemia. ALL, ASP, HTG
24  2016 Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma. DRAE, IFN
25  2015 Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. anti-ASNase, EFS
26  2015 Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon. CHB, ETV, HBsAg, IFN, LAM, NAs
27  2015 Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. DAAs, HCV, IFN, RBV
28  2015 Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial. CHC, HOMA-IR, IFN, IR, RBV, SVR
29  2015 Interventions for dialysis patients with hepatitis C virus (HCV) infection. CKD, HCV, RCTs
30  2015 Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. GT, HCV, LT, RBV, RVR, SVR, TVR
31  2015 Patterned Threadlike Micelles and DNA-Tethered Nanoparticles: A Structural Study of PEGylated Cationic Liposome-DNA Assemblies. CL-DNA NPs, cryo-EM
32  2015 Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. CHC, DAA, GT, IFNL, RBV, SVR
33  2015 Self-reported need for psychotherapy predicts interferon-induced depression in hepatitis C: stratification for interferon-free treatment. ADAPT, AUC, CHC, HADS, IFN, PT
34  2015 Stealth Amphotericin B nanoparticles for oral drug delivery: In vitro optimization. AmB, DEE, FTIR, MPS, NPs, PVP
35  2015 Tenofovir-best hope for treatment of chronic hepatitis B infection? HBeAg, HCC
36  2014 Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. CENTRAL, CI, RR
37  2014 Can pegylated interferon alpha 2a cause development of thyroid disorders in patients with chronic hepatitis B? CHB, TAbs, TPOAb, TSH
38  2014 Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response. CHC, HCC, HCV, IFN, SVR
39  2014 Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin. CSF, HCV
40  2014 Effect of peripherally administered leptin antagonist on whole body metabolism and bone microarchitecture and biomechanical properties in the mouse. SMLA
41  2014 Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. HCV, IFN, SVR
42  2014 Pegylated feline granulocyte colony-stimulating factor increases neutrophil levels in cats. Fe, G-CSF, HuG-CSF
43  2014 Ribavirin improves the IFN-gamma response of natural killer cells to IFN-based therapy of hepatitis C virus infection. HCV, IFN, NK, RBV, STAT
44  2014 [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C]. AST, CHC, ETR, EVR, HCV, IFNA, RVR
45  2013 Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. CENTRAL, CI, MD, RR
46  2013 Association between an IL-28B genetic polymorphism and the efficacy of the response-guided pegylated interferon therapy in children with chronic hepatic C infection. HCV, IFN, IL-28B, SVR
47  2013 Can antidepressants prevent pegylated interferon-alpha/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials? CHC, SSRIs, SVR
48  2013 Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. HCC, HCV, IFN
49  2013 IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. CHB, CI, HBeAg, HBsAg, HBV, IFN, IL, OR
50  2013 Novel biocompatible nanoreactor for silica/gold hybrid nanoparticles preparation. ---
51  2013 Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. ART, HIV, HIV-1
52  2013 Prevention of hemolysis-induced organ damage by nutritional activation of the vagal anti-inflammatory reflex*. IL
53  2013 RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs. HCV, RdRp
54  2013 [Clinical features of antiviral therapy in 12 patients with hepatitis C virus-related cirrhosis after splenectomy]. cE, HCV, VR
55  2013 [Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy]. HCV, IFN, PBMCs, PD-1
56  2013 [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients]. CHC, HCV, IFN, RBV
57  2013 [Study of using an individualized treatment strategy to treat patients with chronic hepatitis C]. CHC, IFN, RBV, RVR, SVR
58  2012 Changes in serum Interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis C genotype 1b infection. CHC, SVR, Th2
59  2012 Deciphering the interleukin 28B variants that better predict response to pegylated interferon-alpha and ribavirin therapy in HCV/HIV-1 coinfected patients. CI, HCV, HIV-1, IFN, IL, OR, RBV, SNPs, SVRs
60  2012 Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study. BCAA, IFN, SVR
61  2012 Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. CNS, EAE, MS
62  2012 Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging. CT, DOX, GNR, PET
63  2012 Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. EOT, HDV, IFN, RCTs, RRs
64  2012 Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. DMFS, EORTC, HR, IFN, OS, RFS
65  2012 Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. HCV, SVR, WT
66  2012 [Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin]. CHC, ETR, HCV, IFNA
67  2011 Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. CHC, HCV, SVR
68  2011 Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region. aa, HCV, IFN, LT, PCR, SVR, VR
69  2011 Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. HDV, IFN, IL
70  2011 Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. CML, GM-CSF, IFN-alpha
71  2011 Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. ER, HCV, IFN, OR
72  2011 Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response. HCV, RBV, RVR, SVR
73  2011 Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance. HCV, IFN, RBV, SVR
74  2011 The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. EV, IFN, RBV, SVR
75  2010 A population pharmacokinetic model for pegylated-asparaginase in children. CL
76  2010 Characterization of hydrogel microstructure using laser tweezers particle tracking and confocal reflection imaging. ---
77  2010 Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. DPPG, FR, FTL-ZOL, L-ZOL, ZOL
78  2010 Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. HCV
79  2010 Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. EVR, IFN, RBV, SVR
80  2010 Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study. CHC, SOC, SVR
81  2010 Interferon-lamda in HCV Infection and Therapy. HCV, IFN
82  2010 Neutralizing antibodies to interferon-alpha and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-alpha-2a and ribavirin (ANRS HC16 GAMMATRI substudy). RIBA
83  2009 An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. ---
84  2009 An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. HCV, IFN, SVR
85  2009 Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. CHC, IFN
86  2009 Efficacy of interferon Beta combined with cyclosporine induction and intensified therapy for retreatment of chronic hepatitis C. HCV, IFN
87  2009 Optimizing the treatment of chronic viral hepatitis C. HCV, RBV, SVR
88  2009 Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis. HCV, IFN, RBV, RCTs, SVR
89  2009 The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. HBV, HCV, IFN, RBV, SVR
90  2009 Therapeutic aspects of hepatitis C in hemodialysis patients. HD, IFN
91  2008 A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. DE, HCV, IFN
92  2008 IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. HCV, IFN, IP-10, NR, SVR
93  2008 Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. ---
94  2008 Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. ALL
95  2008 Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy. HCV, IFN
96  2008 Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas. ---
97  2008 Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. SIL
98  2008 Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. BEV, CT, IL-18, PD, PFS, PR, SD
99  2008 Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection. AUC, IFN, MU, RBV, SVR
100  2008 Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection. ---